心肌梗塞是常見導致緊急住院且高死亡率的急症，過去研究皆顯示-blocker的使用可顯著降低心肌梗塞的復發及死亡率；故本研究希望了解目前本院對心肌梗塞病患於住院期間及出院後之-blocker處方情形。本研究以回溯性分析，收集2000年1月至2002年12月間其主診斷為急性心肌梗塞（AMI）之住院病患，共112位。由研究結果顯示，本院病患住院時-blocker之處方率與病患是否為-blocker適用者並無相關性；本院心肌梗塞病患處方-blocker比率在住院期間為67.0%，出院時為46.5%，出院後3個月為24.1%，出院後6個月為22.3%。本研究建議藥師應積極介入心肌梗塞病患處方-blocker之適當性評估並加強不良反應監測、用藥指導與出院後之用藥追蹤，期能提昇病患用藥之配合度及降低疾病死亡率。

Previous studies have indicated that the therapy of -blockers reduces significantly the rate of relapse and mortality in patients with myocardial infarction (MI).  This present study focused on gaining an insight into the prescribed use of -blocker in MI patients during the hospitalization and at hospital discharge.  Based on a retrospective analysis, altogether 112 patients with a main diagnosis of acute MI (AMI) were collected from Jan. 2000 to Dec. 2002.  The result showed that the -blocker prescription rate was not significantly different between patients who were ideal for the -blocker therapy and patients who were contraindicated for the therapy. While the -blocker prescription rate for MI patients during their hospitalization is 67.0%, it was reduced to 46.5%, 24.1% and 22.3% on the day of discharge, 3 and 6 months after discharge, respectively.  This present study concluded that the pharmacist should play an active role in evaluating the prescribed use of -blocker in MI patients, monitoring the adverse drug reactions, providing patient counseling on drug uses and improving patient’s adherence, thereby reducing the morbidity and mortality of MI.